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Background: Pancreatic metastases (PMs) are rare and lack of guidelines for diagnosis and treatments .The aim of
this study is to explore the diagnosis, treatment, and prognosis of pancreatic metastases.
Methods: Twenty-two patients with pancreatic metastases who had been hospitalized at the First Affiliated
Hospital of China Medical University from October 1980 to October 2012 were included in the present retrospective
study. Seven patients had gastric cancer, five had colon cancer, two each had lung and liver cancer, and one each
had bladder cancer, gallbladder cancer, breast cancer, nasopharyngeal cancer, renal cell carcinoma, and carcinoid.
Results: No specific syndrome or imageological change was found for the pancreatic metastases. The most
common symptoms were abdominal pain and jaundice. Hypo-echoic lesions with well-defined margins were found
on ultrasonic examinations, and low-density lesions with heterogeneous enhancement were identified in CT
images. Nineteen of the 22 received treatment. Three of the 8 patients (34.1%) that had undergone operation
experienced complications, but all patients recovered after conventional treatment. Follow-up studies were performed
for 17 patients (77.3%), and the median survival time from the diagnosis of pancreatic metastases was 13.2 months
(range, 2 to 68 months). Of the five patients who underwent radical resection, one was lost to follow-up, one died at
fifteen months postoperation, and the other three are still alive and free from disease (disease-free survival ranging
from five to thirty-three months from the diagnosis of the pancreatic metastases).
Conclusion: Pancreatic metastases are rare lesions with no specific symptoms. Radical resection should be performed
if possible; however, aggressive treatment should be performed for unresectable pancreatic metastases.
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Most pancreatic cancers are primary tumors, and pan-
creatic metastases (PMs) are actually quite rare, with
only 2% of pancreatic cancers representing PMs [1].
Moreover, most PMs are accompanied by additional me-
tastases outside of the pancreas. No guidelines have been
developed for the diagnosis and treatments of PMs;
therefore, the appropriate treatment for PMs remains
controversial. Here, we retrospectively analyzed the clin-
ical data from 22 patients with PMs to investigate their
diagnosis and treatment.* Correspondence: songsw10@hotmail.com
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The characteristics of the 22 patients included in this
study are shown in Table 1. Among these patients, there
were 13 men and 9 women. The median age of the pa-
tients was 61 years (range, 43 to 86 years). Lesions at the
head and neck of the pancreas were found in 17 patients,
while lesions at the tail of the pancreas were found in 5
patients. Twenty patients had a single tumor, while two
patients had multiple tumors. No diffuse enlargement
of the pancreas was found. The mean longest diameter
of the tumors was 3.07 cm (range, 1.2 to 10.0 cm).The primary tumor and time from diagnosis of primary
tumor to PMs
The primary tumors of the twenty-two patients with
PMs were as follows: gastric cancer in seven patients,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics of the 22 patients
Parameter Value
Number 22
Male, n (%) 13 (59.1%)
Median age (interquartile range) 61 (52 to 65) years
Primary tumor, n (%)
Gastric cancer 7 (31.8%)
Colon cancer 5 (22.7%)
Liver cancer 2 (9.1%)
Lung cancer 2 (9.1%)
Others 6 (27.3%)
Longest diameter of the tumor (mean) 1.2 to 10.0 (3.07) cm
Location of the tumor
Pancreatic head 17
Pancreatic body or tail 5
Single tumor, n (%) 20 (90.9%)
Time between the diagnosis of primary
tumor and PMs (mean)
1 to 192 (55) months
Patients with symptoms, n (%) 18 (81.8%)
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patients, liver cancer in two patients, bladder cancer in
one patient, gallbladder cancer in one patient, nasopha-
ryngeal cancer in one patient, renal cell carcinoma in
one patient, breast cancer in one patient, and carcinoid
in one patient. The mean time between the diagnosis of
the primary tumor and PMs was 55 months (range, 1 to
192 months). The longest time between the diagnosis of
primary tumor and PMs was found in a patient that had
been diagnosed with colon cancer sixteen years before
the diagnosis of PMs, while the primary tumor and PMs
were diagnosed at the same time in the other five
patients (two with primary colon cancer, one with gastric
cancer, one with carcinoid, and one with lung cancer).Diagnostic methods for PMs
For the twenty-two patients with PMs, five patients
were diagnosed by pathological examinations, five were
diagnosed by cytological examinations using fine-needle
aspirate biopsy, and the other patients were diagnosed
by clinical symptoms, imaging examinations (including
ultrasonic examination, computed tomography (CT),
magnetic resonance imaging (MRI), and positron
emission tomography-CT (PET-CT), and history of
malignancies.Results
Pancreatic metastasis-related initial symptoms
No specific symptoms were found for the patients with
PMs. The major initial symptoms of these patients
were jaundice (9 patients, 50%) and discomfort or pain
in the upper abdomen (8 patients, 44.4%). The initial
symptom of one case was acute pancreatitis, and the
other symptoms included gastrointestinal hemorrhage,
nausea, and vomiting. For four other patients, PMs
were diagnosed when patients came to the hospital for
re-examination of the primary tumors but were
asymptomatic.
Imaging findings
Ultrasonic examination was performed for 19 patients,
and the most common findings were heterogeneous or
homogeneous hypo-echoic lesions with well-defined
margins and mild expansion of the pancreatic ducts. CT
scanning was performed for 18 patients and revealed
low-density lesions in the pancreas for most of the pa-
tients. The metastases of sixteen of the 18 patients who
received CT scanning were also found without enhance-
ment or with mild or heterogeneous enhancement, but
the CT numbers were still lower than the pancreatic
parenchymal density even after the enhancement. An-
other patient with clear cell renal cell carcinoma as the
primary tumor was found to have substantial enhance-
ment. MRI examination found no obvious abnormalities
in one patient; however, another patient was found with
an equisignal on T1WI and mildly increased signal on
T2WI. PET-CT scanning showed significantly increased
18flourodeoxyglucose (FDG) uptake in the lesions within
the pancreas.
Treatments
Nineteen of the 22 patients received treatment, while
the other 3 patients refused treatment. Eight of the nine-
teen patients who requested treatment underwent sur-
gery, including radical resection of the tumor for five
patients (four received pancreaticoduodenectomy and
one with primary colon cancer received right hemico-
lectomy and resections of the spleen, pancreatic body,
and pancreatic tail) and palliative operation for three pa-
tients. Four of the nineteen patients received interven-
tional operation, including biliary stent implantation for
three patients, pancreatic arterial infusion chemotherapy
for one patient, and radiotherapy or chemotherapy for
seven patients.
Survival
We called all patients to follow-up in December 2009
and obtained information from 17 patients (77.27%).
The median survival time of these 17 patients was
13.2 months (range, 2 to 68 months). For the five patients
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was five to thirty-three months for three patients after
treatment. The longest survival time (68 months) was
found in a patient with primary colon cancer.
Discussion
Pancreatic metastases (PMs) are very rare, accounting
for only about 2% of malignancies of the pancreas [1].
In a large autopsy series, the prevalence of PMs was
reported to be as high as 6 to 11% [2]. Studies have
reported that people of about 60 years old are at high
risk of developing PMs; however, no significant gender
difference has been reported [3], which is in agreement
with the findings of the present study (median age,
61.5 years; male/female ratio of 1.4:1). Renal cell carcin-
oma appears to be the most common primary tumor to
cause secondary pancreatic tumors for people outside of
China [3,4]. In Chinese individuals with PMs, lung
cancer (especially small cell lung cancer) has been
reported to be the most common primary tumor [5-7],
followed by gastric and colon cancers. Renal cell carcin-
oma accounts for very few patients with PMs in China.
We believe that the widespread smoking in China could
cause increased risk of lung cancer, and small cell lung
cancer can develop very quickly, thus permitting the
rapid formation of distal metastases. The findings of
the present study showed that most patients with PMs
had primary gastric cancer or colon cancer, which could
partly be affected by the regional distribution of
different cancers.
Generally, primary cancers require a long time to
spread to the pancreas, especially for renal cell carcin-
oma. Studies have reported that the median time for
renal cell carcinoma to spread to the pancreas is
13 years, while that for other cancers is 4 years [8]. For
some special cases, PMs could develop with the primary
tumors almost simultaneously [9]. The mean time
between the diagnosis of primary tumor and PMs was
55 months in the present study, which is consistent with
previous reports.
No specific symptoms or imaging features were found
for PMs. Studies [4] have reported that the most com-
mon symptoms of PMs include abdominal pain, jaun-
dice, and gastrointestinal hemorrhage. In addition, for
patients with primary lung cancer, acute pancreatitis
could be the initial symptom. The main feature on ultra-
sonic examination is hypo- or mixed echoic lesions [5].
The main feature in CT imaging is low-density lesions
without enhancement or with heterogeneous enhance-
ments; however, for patients with substantial enhance-
ments in the lesion and a history of renal carcinoma, renal
cell carcinoma should be strongly considered as the pri-
mary tumor of the PMs. In the present study, pathologicalexamination showed that one patient had PMs that had
spread from renal cell carcinoma, and the CT image re-
vealed a large blood supply, while a smaller blood supply
was generally found in other patients. Other features, in-
cluding double duct signs, peripancreatic infiltration, and
distant metastasis, could also be found. MRI examinations
generally reveal hypo- or equisignals on T1WI images and
hypersignals or mildly increased signals on T2WI images;
however, the signals are generally heterogeneous. En-
hanced scanning generally reveals ring-enhancement, and
the gaps between the peripancreatic fat tissues could be
displayed clearly with mild expansion of the pancreatic
ducts, but without invasion of adjacent vessels [10]. Only
very few studies have reported the features of PET-CT im-
ages of PMs. However, PET-CT could effectively display
micrometastases all over the body, which could help in
choosing the appropriate treatment method. In the
present study, two patients were examined with PET-
CT and were found to have lesions exhibiting increased
FDG uptake, but no other abnormalities. These two pa-
tients were successfully treated with radical surgery.
Postoperative pathological examination is essential for
the diagnosis of PMs. In the present study, five patients
were diagnosed by postoperative pathological examina-
tions, another five patients were diagnosed by cyto-
logical examinations using fine-needle aspirate biopsy;
the other patients were diagnosed by clinical symptoms,
imaging presentations, and history of malignancies. Previ-
ous disease history plays a critical role in the differential
diagnosis, while cytological examination by fine-needle
aspirate biopsy is not recommended as a routine pre-
operative examination as it could possibly introduce
peritoneal dissemination of the tumor [11].
The treatment for PMs remains controversial. Since
most patients with PMs are at advanced stages and gener-
ally with systemic metastasis, operation is not appropriate.
Fortunately, the advances made in pancreatic surgery in
recent years have greatly increased the safety of the oper-
ation; this has extended the indications for surgery, and
patients with PMs can now also be treated this way. How-
ever, no guidelines on the treatment of patients with PMs
have been issued to date, except for a single paper, focused
on the surgical treatment of PMs, which was published in
The Lancet [4] in 2009 and which provided valuable infor-
mation on treating PMs.
According to the guidelines issued by Reddy and
Wolfgang and other studies [3], several characteristics
are required for treating PMs with radical surgery: first,
the primary cancer type should be associated with suc-
cessful outcomes; second, the primary cancer site has
been well controlled; third, the PMs should be proven
as isolated metastases; fourth, the PMs should not involve
invasion of the adjacent vessels, and the clinicians should
consider the resectability of the metastasis; and fifth, the
Figure 1 Comparison of colon cancer and gastric cancer prognosis.
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ation. However, although invasion of the peripancreatic
veins is not a contraindication for the operation, clinicians
should be very careful in treating such patients. In the
present study, all patients who received radical surgery
had isolated metastases, and the primary cancer sites in
these patients had been well controlled. Follow-up studies
revealed no signs of recurrence, and the patients generally
had excellent long-term outcomes.
Currently, researchers believe that radical surgery
should be performed in treating isolated single PMs as
often as possible [1,8,9,11]; however, the treatment of
isolated multiple PMs still remains controversial. Sev-
eral researchers have proposed that total pancreatec-
tomy should be performed for these patients because
multiple PMs could involve the entire pancreas. In con-
trast, other researchers believe that such patients should
not be treated surgically because the presence of mul-
tiple PMs indicates fatal generalized dissemination [12].
Interestingly, Sellner et al. [13] have reported that pa-
tients with single PMs or isolated multiple PMs haveTable 2 Recent published series of patients with pancreatic m












Present study 22 2 (9.1% ) 1 (4.5%) 7 (31.8%) 2%
Markinez [20], 2013 8 0 8 (100%) 0 1.2%
Boo SJ [21], 2011 31 9 (29%) 16 (51.6%) 1 (3.2%) NR
Reddy S [17], 2008 49 4 (8.2%) 21 (42.9%) 0 NR
Zerbi A [22], 2008 36 0 36 (100%) 0 NR
Sellner F [13], 2006 236 0 236 (100%) 0 NR
Xu DK [5], 2006 18 8 (44.4%) 1 (5.6%) 2 (11.1%) 15%
NR: not reported.similar three- and five-year survival rates; thus, radical
operation could be performed for patients with isolated
multiple PMs. In addition, studies have demonstrated
that patients are at a high risk of developing diabetes
after total pancreatectomy. Therefore, Bassi et al. [14]
performed irregular or subtotal pancreatic resection
when treating such patients; however, a high incidence
of complications and high local recurrence rates were
reported.
For some cases in which extensive tumor metastases
have been found during the operation and in which pan-
creatic resection could not be performed, palliative sur-
gery, including Roux-en-Y biliary-jejunal anastomosis,
gastrojejunostomy, and biliary stent implantation, should
be the treatment of choice to remove the obstruction
from the biliary tract and duodenum, which could also
improve patient quality of life. In the present study, two
patients received biliary-intestinal anastomosis, one re-
ceived cholecystostomy, and four received biliary stent im-
plantation for the treatment of obstructive jaundice.
Comprehensive treatment, including radiotherapy and
chemotherapy, should be the treatment of choice for pa-
tients with PMs and systemic metastasis. However, differ-
ent treatment methods should be performed for different
patients depending on the primary tumor. In brief,
chemotherapy should be performed for PMs patients
with primary lung cancer, especially small cell lung cancer,
which could result in early metastasis. In patients with
renal cell carcinoma that has spread to the pancreas, treat-
ment with IFN-α and IL-2 used to be common; however,
several new drugs, including temsirolimus, bevacizumab,
sunitinib, and sorafenib, have proven to be effective in
treating such diseases. Moreover, the latter two drugs,
namely sunitinib and sorafenib, have been approved by
the Food and Drug Administration (FDA) as second-
line treatments that should be used if the patients do
not respond to cytokine therapy. These new drugs are
also applicable for patients with advanced renal cell








2 year 5 year
55 (1 to 92) 18 (81.8%) 2 (9.1% ) 35.3% 11.8%
149 (19 to 361) NR 3 (37.5%) 37.5% 12.5%
40.8 (3 to 186) NR 6 (19.4%) NR NR
4.8 45 (92%) 7 (14%) NR NR
8 8 (22%) 0 95% 88%
10 66 (65%) 23 (12%) 78% 72%
12 (3 to 216) NR 4 (22.2%) NR NR
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searchers have highlighted the importance of systemic
comprehensive treatments in treating pancreatic metasta-
ses from renal cell carcinoma, and operative treatment
should only be considered as a part of multimodal therapy
or combination treatment instead being the sole treatment
method [15,16]. We believe that further studies should be
performed to investigate the most appropriate compre-
hensive treatment for unresectable PMs.
Generally, the outcomes of PMs are better than those
of primary pancreatic cancers [11], and several other fac-
tors affect these outcomes. Many studies [17-19] have
demonstrated that the most important factor affecting
the outcome of PMs is the pathological type of the pri-
mary tumor. The best and worst outcomes have been
found in patients with primary renal cell carcinoma and
lung cancer, respectively. The 5-year survival rate for pa-
tients with primary renal cell carcinoma is 29%, and the
median survival time is 54 months; for the patients with
primary lung cancer, the median survival time is only
6 months [4,5,19]. In the present study, the median sur-
vival time was 27 months from the diagnosis of PMs for
patients with primary colon cancer, and the outcomes of
these patients were better than those in patients with
gastric cancer (Figure 1). The mean disease-free survival
of patients with primary renal cell carcinoma was
16 months from the operation. The longest survival
time was found in a patient with primary colon cancer
that had spread to the pancreas after operation. For
this patient, pancreatic artery perfusion therapy has
been performed regularly, and the patient has survived
for more than 68 months with the tumor; examinations
have also revealed signs of tumor regression. Several
studies have suggested that radical surgery is a favor-
able factor for the prognosis of patients with PMs
[13,18]. In the present study, better long-term out-
comes were found in patients who received radical sur-
gery. In brief, among the five patients who were treated
with radical surgery, one died at fifteen months post-
operation, one was lost to follow-up, and the other
three patients are living disease-free at the time of
writing this manuscript, giving a mean survival time of
18 months after the surgical treatment of PMs. In con-
trast, the mean survival time of patients who were
treated with palliative treatment and follow-up was
only 6.8 months after the diagnosis of PMs. In Table 2,
we showed the recent published series of patients with
pancreatic metastases.
Conclusions
Pancreatic metastases are rare lesions without specific
symptoms. Radical resection should be performed if pos-
sible; however, multiple treatment should be performed
for unresectable pancreatic metastases. However, the samplesize of the present study was small, and further studies are
needed to validate our findings and to identify the factors
that affect the prognosis of PMs.
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